192 related articles for article (PubMed ID: 32430254)
1. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V
Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
Luo Y; Feng B; Wei D; Han Y; Li M; Zhao J; Lin Y; Hou Z; Jiang Y
Sci Rep; 2020 Oct; 10(1):17674. PubMed ID: 33077839
[TBL] [Abstract][Full Text] [Related]
3. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M
Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
D'Andrea D; Matin S; Black PC; Petros FG; Zargar H; Dinney CP; Cookson MS; Kassouf W; Dall'Era MA; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; Sridhar SS; North S; Barocas DA; Lotan Y; Stephenson AJ; van Rhijn BW; Spiess PE; Daneshmand S; Shariat SF
BJU Int; 2021 May; 127(5):528-537. PubMed ID: 32981193
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy increases survival and downstaging of upper tract urothelial cancer.
Davaro F; May A; McFerrin C; Raza SJ; Siddiqui S; Hamilton Z
Can J Urol; 2019 Oct; 26(5):9938-9944. PubMed ID: 31629443
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma.
Martini A; Falagario UG; Waingankar N; Daza J; Treacy PJ; Necchi A; Galsky MD; Sfakianos JP
Urol Oncol; 2020 Aug; 38(8):684.e9-684.e15. PubMed ID: 32284255
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort.
Matsunaga T; Komura K; Hashimoto T; Muraoka R; Satake N; Tsutsumi T; Tsujino T; Yoshikawa Y; Takai T; Minami K; Taniguchi K; Tanaka T; Uehara H; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Ohno Y; Azuma H
World J Urol; 2020 Dec; 38(12):3183-3190. PubMed ID: 32065276
[TBL] [Abstract][Full Text] [Related]
9. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
Zennami K; Sumitomo M; Takahara K; Nukaya T; Takenaka M; Fukaya K; Ichino M; Fukami N; Sasaki H; Kusaka M; Shiroki R
BJU Int; 2021 Mar; 127(3):332-339. PubMed ID: 32896105
[TBL] [Abstract][Full Text] [Related]
10. Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma.
Gin GE; Ruel NH; Kardos SV; Sfakianos JP; Uchio E; Lau CS; Yuh BE
Urol Oncol; 2017 May; 35(5):192-200. PubMed ID: 28041996
[TBL] [Abstract][Full Text] [Related]
11. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
[TBL] [Abstract][Full Text] [Related]
12. Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.
Almassi N; Gao T; Lee B; Stein RJ; Haber GP; Ornstein MC; Rini BI; Gilligan TD; Garcia JA; Stephenson AJ; Grivas P
Clin Genitourin Cancer; 2018 Dec; 16(6):e1237-e1242. PubMed ID: 30217764
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM
J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680
[TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Rieken M; Xylinas E; Kluth L; Trinh QD; Lee RK; Fajkovic H; Novara G; Margulis V; Lotan Y; Martinez-Salamanca JI; Matsumoto K; Seitz C; Remzi M; Karakiewicz PI; Scherr DS; Briganti A; Kautzky-Willer A; Bachmann A; Shariat SF;
Eur J Surg Oncol; 2014 Jan; 40(1):113-20. PubMed ID: 24113620
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of upper tract urothelial carcinoma with isolated lymph node involvement following surgical resection: implications for multi-modal management.
Pelcovits A; Mueller-Leonhard C; Mega A; Amin A; Kim SP; Golijanin D; Gershman B
World J Urol; 2020 May; 38(5):1243-1252. PubMed ID: 31388818
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Preoperative Albumin-Globulin Ratio on Oncologic Outcomes in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
Xu H; Tan P; Ai J; Huang Y; Lin T; Yang L; Wei Q
Clin Genitourin Cancer; 2018 Oct; 16(5):e1059-e1068. PubMed ID: 29980449
[TBL] [Abstract][Full Text] [Related]
17. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy.
Fletcher SA; Pallauf M; Watts EK; Lombardo KA; Campbell JA; Rezaee ME; Rouprêt M; Boorjian SA; Potretzke AM; Roshandel MR; Ploussard G; Djaladat H; Ghoreifi A; Mari A; Campi R; Khene ZE; Raman JD; Kikuchi E; Rink M; Abdollah F; Boormans JL; Fujita K; D'Andrea D; Soria F; Breda A; Hoffman-Censits J; McConkey DJ; Shariat SF; Pradere B; Singla N
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38262800
[TBL] [Abstract][Full Text] [Related]
18. Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
Song W; Jeong JY; Jeon HG; Seo SI; Jeon SS; Choi HY; Lee HM; Sung HH
Int J Surg; 2019 Jun; 66():12-17. PubMed ID: 31018160
[TBL] [Abstract][Full Text] [Related]
19. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Eur Urol Focus; 2018 Dec; 4(6):946-953. PubMed ID: 28753881
[TBL] [Abstract][Full Text] [Related]
20. Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract.
Chung PH; Krabbe LM; Darwish OM; Westerman ME; Bagrodia A; Gayed BA; Haddad AQ; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
Urol Oncol; 2014 Oct; 32(7):981-8. PubMed ID: 25022858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
